Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

Abstract A desmoplastic colorectal cancer stroma, characterized by excess turnover of the cancer-associated fibroblast derived collagens type III and VI, can lead to reduced drug-uptake and poor treatment response. We investigated the association between biomarkers of collagen type III and VI and ov...

Full description

Bibliographic Details
Main Authors:	Neel I. Nissen, Stephanie Kehlet, Mogens K. Boisen, Maria Liljefors, Christina Jensen, Astrid Z. Johansen, Julia S. Johansen, Janine T. Erler, Morten Karsdal, Joachim H. Mortensen, Anette Høye, Nicholas Willumsen
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-01-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-020-79608-0

Similar Items

Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer
by: Marina Crespo-Bravo, et al.
Published: (2023-10-01)

1435 Interleukin-8 activates fibroblast and could act as a potential combinational immune-stroma therapy target
by: Nicholas Willumsen, et al.
Published: (2023-11-01)

Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology
by: Neel I. Nissen, et al.
Published: (2019-03-01)

Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma
by: Neel I. Nissen, et al.
Published: (2022-02-01)

Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy
by: Christina Jensen, et al.
Published: (2021-10-01)

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
by: Mogens K Boisen, et al.
Published: (2014-01-01)

High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma
by: Neel I. Nissen, et al.
Published: (2023-03-01)

In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker
by: Patryk J. Drobinski, et al.
Published: (2022-12-01)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
by: Astrid Z. Johansen, et al.
Published: (2023-09-01)

36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors
by: Marco Donia, et al.
Published: (2023-11-01)

Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors
by: Jeppe Thorlacius-Ussing, et al.
Published: (2022-04-01)

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
by: Christina Jensen, et al.
Published: (2018-12-01)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
by: Cornelia Schuster, et al.
Published: (2023-09-01)

Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
by: Emilie A. Madsen, et al.
Published: (2022-11-01)

Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy
by: Zhiming Wang, et al.
Published: (2016-09-01)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
by: Marisi G, et al.
Published: (2018-11-01)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
by: Ping-Chih Hsu, et al.
Published: (2023-01-01)

Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix.
by: Stephanie N Kehlet, et al.
Published: (2018-01-01)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
by: Yanxin Liu, et al.
Published: (2023-03-01)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
by: Giorgia Marisi, et al.
Published: (2017-05-01)

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
by: Dominiek Smeets, et al.
Published: (2018-10-01)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
by: Diana Cornelia Moisuc, et al.
Published: (2023-02-01)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
by: Chikako Funasaka, et al.
Published: (2019-08-01)

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
by: Eduardo Díaz-Rubio, et al.
Published: (2012-01-01)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008-03-01)

Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibrogenesis
by: Rasmus S. Pedersen, et al.
Published: (2022-09-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
by: Dallas B. Flies, et al.
Published: (2023-08-01)

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
by: Kunpeng Fang, et al.
Published: (2024-02-01)

Bevacizumab in metastatic breast cancer: when may it be used?
by: Shari B. Goldfarb, et al.
Published: (2011-03-01)

Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
by: Agarwal Vijay, et al.
Published: (2008-07-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
by: S Whyte, et al.
Published: (2010-10-01)

Overvægt fra børnehøjde
by: Anette Johansen
Published: (2003-05-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
by: Ronald M Bukowski
Published: (2010-03-01)

Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders
by: Christina Jensen, et al.
Published: (2018-09-01)

Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls
by: Christina Jensen, et al.
Published: (2023-04-01)

Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
by: Alessandro Passardi, et al.
Published: (2023-12-01)

Resource Estimations in Contingency Planning for Foot-and-Mouth Disease
by: Anette Boklund, et al.
Published: (2017-05-01)